Brigatinib under the microscope: how does it really perform in korean patients?
NCT ID NCT04592523
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study monitors the safety and effectiveness of brigatinib in adults with advanced ALK-positive non-small cell lung cancer in South Korea. Researchers will track side effects and tumor response in 257 patients who start brigatinib for the first time. The goal is to see how well the drug works in everyday medical practice, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pusan National University Hospital
RECRUITINGBusan, 49241, South Korea
Conditions
Explore the condition pages connected to this study.